Is Option B+ the best choice?

Only 30% of eligible pregnant women are accessing treatment--substantially less than the general population.3 Option B+ was developed in Malawi to overcome barriers women face in accessing PMTCT and treatment services.4 In 1 year, Malawi achieved a sevenfold increase in the number of pregnant and br...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2013-04, Vol.381 (9874), p.1272-1272
1. Verfasser:	Goosby, Eric P
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Anti-Retroviral Agents - administration & dosage Antiretroviral agents Breast feeding Female HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Infectious Disease Transmission, Vertical - prevention & control Internal Medicine Pregnancy Pregnancy Complications, Infectious - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Only 30% of eligible pregnant women are accessing treatment--substantially less than the general population.3 Option B+ was developed in Malawi to overcome barriers women face in accessing PMTCT and treatment services.4 In 1 year, Malawi achieved a sevenfold increase in the number of pregnant and breastfeeding women starting antiretroviral therapy.5 Several other countries (including Rwanda, Haiti, and Uganda) have since adopted Option B+.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(13)60832-6